U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Vaccines, Blood & Biologics
  3. Whole Blood and blood components (Convalescent Plasma, High Titer, Anti-SARS-CoV-2 (Whole Blood-derived) and Apheresis Convalescent Plasma, High Titer, Anti-SARS-CoV-2)
  1. Vaccines, Blood & Biologics

Whole Blood and blood components (Convalescent Plasma, High Titer, Anti-SARS-CoV-2 (Whole Blood-derived) and Apheresis Convalescent Plasma, High Titer, Anti-SARS-CoV-2)

STN: 101766
Proper Name: Whole Blood and blood components (Convalescent Plasma, High Titer, Anti-SARS-CoV-2 (Whole Blood-derived) and Apheresis Convalescent Plasma, High Titer, Anti-SARS-CoV-2)
Tradename: N/A
Manufacturer: OneBlood, Inc.
Indication:

  • Treatment of COVID-19 in patients with immunocompromise-immunosuppressive disease/process or receiving immunosuppressive treatments at risk of severe disease progression in either the inpatient or outpatient setting.

Product Information

Supporting Documents

Back to Top